Cubist Systematic Strategies’s BridgeBio Pharma BBIO Stock Holding History

Cubist Systematic Strategies’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,100	Closed	-$140K	–	2862
2024 Q4	$140K	Hold	5,100	–	–	﹤0.01%	2656
2024 Q3	$130K	Sell	5,100 -9,200	-64%	-$242K	﹤0.01%	2656
2024 Q2	$362K	Hold	14,300	–	–	﹤0.01%	2277
2024 Q1	$442K	Hold	14,300	–	–	﹤0.01%	2683
2023 Q4	$577K	Hold	14,300	–	–	﹤0.01%	2446
2023 Q3	$377K	Buy	+14,300	New	+$406K	﹤0.01%	2474

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cubist Systematic Strategies's BBIO Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in BridgeBio Pharma (BBIO) in Q3 2025: 28,668 shares worth $1.49M. The stake represents 0.01% of the portfolio and ranks #1740 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in BBIO as recently as Q4 2023.

Cubist Systematic Strategies first reported a position in BBIO in Q3 2020 and has held it in 13 quarters since. The position peaked at $4.56M in Q3 2022. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

Cubist Systematic Strategies held 28,668 shares of BridgeBio Pharma worth $1.49M as of Q3 2025.
BridgeBio Pharma was a new Cubist Systematic Strategies position in Q3 2025.
BridgeBio Pharma made up 0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1740 holding.
Cubist Systematic Strategies first reported a position in BridgeBio Pharma in Q3 2020 and has held it in 13 quarters since.
Cubist Systematic Strategies's BridgeBio Pharma position peaked at $4.56M in Q3 2022.
392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.